Furthermore, using a C5aR knock-in mouse model, the study showed that administration of anti-C5aR monoclonal antibodies eliminated C5aR-mediated activation and infiltration of myeloid cells thus preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients [98]. This evidence concerns the gene C5AR1 and COVID-19.